Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. - Wikidata - wikimedia - TriplyDB

Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.

Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.

http://www.wikidata.org/entity/Q37119856

about

Sclerostin Inhibition in the Management of Osteoporosis Methylprednisolone exerts neuroprotective effects by regulating autophagy and apoptosis.Curcumin improves bone microarchitecture in glucocorticoid-induced secondary osteoporosis mice through the activation of microRNA-365 via regulating MMP-9.Role and mechanism of action of sclerostin in bone.Osteoporosis and autophagy: What is the relationship?A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis.Insulin-like growth factor 1 inhibits autophagy of human colorectal carcinoma drug-resistant cells via the protein kinase B/mammalian target of rapamycin signaling pathway.Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.Sclerostin Blockade-A Dual Mode of Action After All?The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis.Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture.

P2860

Q26750713-08C0CDBC-87FE-450E-8080-D4C5C8DB8C1B Q36059599-4304E6F0-7487-4722-B3A4-B424E506B99A Q36511687-98789620-E159-4E16-993E-1644CCB91D08 Q38807230-321891BA-F9CF-4DDD-B206-E6B79B581137 Q39206865-9E5A763E-3127-4DD1-B10B-024CB5135711 Q46224268-8DF34496-C68D-46F1-BE05-1F02FEA6A95D Q47275620-A3E99778-24F7-4DB2-97EF-85D28CF6C3F2 Q47977236-5A523597-7390-44D3-8A89-E7BEBDF81DE6 Q50975008-CEBE7E17-85E1-44E8-AF70-E24C42F78A7B Q54035461-0D2C2748-E1F0-4EC8-9374-4C7C137B698F Q55240717-35448A0C-57F0-4624-B021-9B292A6EF68A Q55261693-28AD332B-3ACE-43B1-9D75-0DFA8B54D5EF

P2860

Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.

http://www.wikidata.org/entity/Q37119856

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 September 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Sclerostin-antibody treatment ...... tained bone mass and strength.

@en

Sclerostin-antibody treatment ...... tained bone mass and strength.

@nl

type

label

Sclerostin-antibody treatment ...... tained bone mass and strength.

@en

Sclerostin-antibody treatment ...... tained bone mass and strength.

@nl

prefLabel

Sclerostin-antibody treatment ...... tained bone mass and strength.

@en

Sclerostin-antibody treatment ...... tained bone mass and strength.

@nl

P1433

Q37119856-C0802ED5-DD39-4CFB-B264-30BDBA003106

P1476

Q37119856-62DF3B14-D707-4428-8E00-3DC56C1E7617

P2093

Q37119856-2CD1590E-23C4-4B82-98CD-C0EF00660353

Q37119856-51E1BE72-DE33-45A1-B928-D3C6D94E7346

Q37119856-81D332C7-439F-49B1-9E65-203408F0DF28

Q37119856-9470E40C-0F6E-489B-99EF-F0520EC0DBB2

Q37119856-9493693B-B329-4590-B489-485DCCD3C53D

Q37119856-9FD684C7-3B5F-4485-9294-F009EBDC7FCF

Q37119856-C6FA0E39-B431-4CA7-89CB-3EAB5674AF18

Q37119856-D148E30A-5080-4243-A50C-0A57E807DE13

Q37119856-F82BC8B5-E1BC-41E3-99F1-7E18980708EC

P2860

Q37119856-08CE2972-9D3B-4FD4-AEA7-A6E57DE6DEF3

Q37119856-18D918B9-1497-4055-BAE7-7ED404A145E0

Q37119856-1906819C-D905-414B-8FE9-1843F0270C99

Q37119856-1D156EA5-98C9-4C6D-B981-EFB524833279

Q37119856-1D2C65BA-BB00-43D3-AC9B-AA1D4A1C05F2

Q37119856-24DCEAD2-168B-4761-8168-35CF4F7F5027

Q37119856-2A1241B2-FDB4-4D14-A019-D6DC7BD94D32

Q37119856-2F4BBB44-D622-4983-B3E0-586EAC24CBA1

Q37119856-3402028D-B1FD-4CCA-9003-AAE0095A00B6

Q37119856-34D8F59B-D8F8-43C4-9B7C-81076535C065

P2888

Q37119856-C18FB3D8-3A0C-440C-A4D2-79E933638ABA

P304

Q37119856-FA98F0AD-6C86-45D4-8549-ADC1BE2972A2

P31

Q37119856-8D25E653-E18B-4B12-9748-8586CD00FD44

P356

Q37119856-4634E48C-4033-4A8E-9F9B-14AB366FE528

P407

Q37119856-90AF9E36-063B-42CE-B651-4F78FB86077E

P433

Q37119856-22BB122F-7B3F-490A-9EEE-ACF7F63F1944

P478

Q37119856-606EB58A-5A89-48CC-8FFA-E305E557CD85

P577

Q37119856-5C7F9286-A7EA-4F02-83F7-D8D5C1B4905A

P698

Q37119856-F39B4889-3538-4128-87CE-C44AAEB38979

P921

Q37119856-3E9018E2-CCF6-44BC-8367-E656333EC614

Q37119856-FE0E9A00-2769-4A23-980D-CF9721043222

P932

Q37119856-2F333F97-0B97-4EDE-AC47-C601FBC24322

P356

S00198-015-3308-6

P1433

Osteoporosis International

P1476

Sclerostin-antibody treatment ...... tained bone mass and strength.

@en

P2093

E Y-A Lay

http://www.w3.org/2001/XMLSchema#string

H Ke

http://www.w3.org/2001/XMLSchema#string

L Jiang

http://www.w3.org/2001/XMLSchema#string

N E Lane

http://www.w3.org/2001/XMLSchema#string

R O Ritchie

http://www.w3.org/2001/XMLSchema#string

W Dai

http://www.w3.org/2001/XMLSchema#string

W Yao

http://www.w3.org/2001/XMLSchema#string

X Li

http://www.w3.org/2001/XMLSchema#string

Z Zhong

http://www.w3.org/2001/XMLSchema#string

P2860

LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

Efficient selection for high-expression transfectants with a novel eukaryotic vector

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis.

Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice.

P2888

s00198-015-3308-6

P304

283-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-015-3308-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26384674

http://www.w3.org/2001/XMLSchema#string

P921

P932

4958115

http://www.w3.org/2001/XMLSchema#string